{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:39:53Z","timestamp":1791023993720,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jaad.2013.02.025","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T06:03:44Z","timestamp":1366265024000},"page":"463-472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer"],"prefix":"10.1016","volume":"69","author":[{"given":"Yoshio","family":"Kiyohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.jaad.2013.02.025_bib1","doi-asserted-by":"crossref","first-page":"vi35","DOI":"10.1093\/annonc\/mdm222","article-title":"Erlotinib in cancer treatment","volume":"18","author":"Bareschino","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2013.02.025_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.02.025_bib3","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e31818d6702","article-title":"Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study","volume":"3","author":"Kubota","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaad.2013.02.025_bib4","first-page":"557","article-title":"Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer","volume":"30","author":"Takahashi","year":"2010","journal-title":"Anticancer Res"},{"issue":"Suppl","key":"10.1016\/j.jaad.2013.02.025_bib5","first-page":"4","article-title":"Clinical presentation and pathophysiology of EGFRI dermatologic toxicities","volume":"21","author":"Mitchell","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaad.2013.02.025_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/tpj.2011.51","article-title":"Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity","volume":"13","author":"Parmar","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaad.2013.02.025_bib7","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"P\u00e9rez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.02.025_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","article-title":"HER1\/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum","volume":"10","author":"P\u00e9rez-Soler","year":"2005","journal-title":"Oncologist"},{"issue":"Suppl","key":"10.1016\/j.jaad.2013.02.025_bib9","first-page":"502s","article-title":"Time course of cutaneous toxicity secondary to erlotinib therapy in patients with non-small cell lung cancer enrolled in the\u00a0SATURN study [abstract]","volume":"29","author":"P\u00e9rez-Soler","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.02.025_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.02.025_bib11","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-06-2610","article-title":"Correlation between development of rash and efficacy in patients treated with epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies","volume":"13","author":"Wacker","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2013.02.025_bib12","first-page":"190","article-title":"Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: integrated analysis of two Japanese phase II studies","volume":"1","author":"Okamoto","year":"2012","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"10.1016\/j.jaad.2013.02.025_bib13","unstructured":"Common Terminology Criteria for Adverse Events [CTCAE] v4.0. US Department of Health and Human Services. National Institutes of Health. National Cancer Institute. May 28, 2009. Available from: URL:http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed April 17, 2012."},{"key":"10.1016\/j.jaad.2013.02.025_bib14","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/JTO.0b013e3182598abb","article-title":"Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR)","volume":"7","author":"Nakagawa","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaad.2013.02.025_bib15","unstructured":"US Department of Health and Human Services. National Institutes of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events [CTCAE] v3.0. August 9, 2006. Available from: URL:http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed April 17, 2012."},{"key":"10.1016\/j.jaad.2013.02.025_bib16","unstructured":"Rash management Ver.3, 2011. Yoshio Kiyohara, Naoya Yamazazki, Chugai Pharmaceutical Co Ltd."},{"key":"10.1016\/j.jaad.2013.02.025_bib17","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.02.025_bib18","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor-inhibitor skin rashes: results of a placebo-controlled trial from North Central Cancer Treatment Group (NO3CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2013.02.025_bib19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaad.2009.03.046","article-title":"A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption","volume":"61","author":"Scope","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.02.025_bib20","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1634\/theoncologist.2010-0082","article-title":"Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from North Central Cancer Treatment Group (N05C4)","volume":"15","author":"Jatoi","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2013.02.025_bib21","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with\u00a0metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.02.025_bib22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.144.7.949","article-title":"Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects","volume":"144","author":"Pomerantz","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.02.025_bib23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaad.2006.06.046","article-title":"Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy","volume":"56","author":"DeWitt","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.02.025_bib24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2133.2005.06835.x","article-title":"Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy","volume":"153","author":"Gutzmer","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.02.025_bib25","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/j.jaad.2009.12.019","article-title":"Effect of adapalene on cetuximab-induced painful periungual inflammation","volume":"64","author":"Hachisuka","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.02.025_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000329914","article-title":"Successful treatment of epidermal growth factor receptor inhibitor-induced periungual inflammation with adapalene","volume":"3","author":"Hachisuka","year":"2011","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2013.02.025_bib27","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1346-8138.2011.01424.x","article-title":"Successful treatment with adapalene of cetuximab-induced acneiform eruptions","volume":"39","author":"Taguchi","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.02.025_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0781.2007.00273.x","article-title":"Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib","volume":"23","author":"Luu","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2013.02.025_bib29","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/archderm.1992.01680180125022","article-title":"The rule of hand: 4 hand areas\u00a0= 2 FTU\u00a0= 1 g","volume":"128","author":"Long","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.02.025_bib30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2230.1991.tb01232.x","article-title":"The finger-tip unit\u2013a new practical measure","volume":"16","author":"Long","year":"1991","journal-title":"Clin Exp Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213002156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213002156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:27:29Z","timestamp":1759271249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213002156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0190962213002156"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.02.025","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}